David Hoang
Stock Analyst at Deutsche Bank
(3.52)
# 890
Out of 5,139 analysts
48
Total ratings
50%
Success rate
7.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Buy | $103 | $80.77 | +27.52% | 1 | Dec 10, 2025 | |
| ALKS Alkermes | Maintains: Buy | $55 → $45 | $31.63 | +42.27% | 3 | Nov 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $280 | $317.25 | -11.74% | 2 | Oct 17, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Buy | $43 | $33.24 | +29.36% | 1 | Sep 26, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $36 | $36.22 | -0.61% | 4 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sell | $6 → $12 | $21.13 | -43.21% | 10 | Aug 15, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $25.99 | +34.67% | 5 | May 21, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $39.98 | +67.58% | 3 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $17.99 | +72.32% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $13.14 | +394.67% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $176 | $177.27 | -0.72% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $21.48 | -44.13% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $132.39 | +19.34% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.89 | +270.37% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.47 | +192.50% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.76 | +325.53% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $359.27 | -38.76% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $63.84 | +25.31% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $2.52 | +19.05% | 1 | Dec 7, 2022 |
Apogee Therapeutics
Dec 10, 2025
Initiates: Buy
Price Target: $103
Current: $80.77
Upside: +27.52%
Alkermes
Nov 13, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $31.63
Upside: +42.27%
Praxis Precision Medicines
Oct 17, 2025
Maintains: Buy
Price Target: $65 → $280
Current: $317.25
Upside: -11.74%
Spyre Therapeutics
Sep 26, 2025
Initiates: Buy
Price Target: $43
Current: $33.24
Upside: +29.36%
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Buy
Price Target: $54 → $36
Current: $36.22
Upside: -0.61%
Sarepta Therapeutics
Aug 15, 2025
Maintains: Sell
Price Target: $6 → $12
Current: $21.13
Upside: -43.21%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $25.99
Upside: +34.67%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $39.98
Upside: +67.58%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $17.99
Upside: +72.32%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $13.14
Upside: +394.67%
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $177.27
Upside: -0.72%
Feb 11, 2025
Initiates: Buy
Price Target: $12
Current: $21.48
Upside: -44.13%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $132.39
Upside: +19.34%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $1.89
Upside: +270.37%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $5.47
Upside: +192.50%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $3.76
Upside: +325.53%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $359.27
Upside: -38.76%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $63.84
Upside: +25.31%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $2.52
Upside: +19.05%